The short answer
LI-RADS is report language that needs context. In liver CT, MRI, or ultrasound reports for people at high risk for liver cancer, it is a system radiologists use to categorize liver findings, from probably benign to definitely hepatocellular carcinoma in the right setting. This page explains the plain-language meaning, limits, likely next questions, and why your care team must interpret it with the rest of your results.
LI-RADS has a specific meaning in liver CT, MRI, or ultrasound reports for people at high risk for liver cancer.
The phrase alone is not the whole diagnosis or treatment plan.
The next step depends on the full report, prior tests, symptoms, and your cancer history.
Ask what the finding changes, what remains uncertain, and when you will review the plan.
Choose how you want to understand this
The full explanation.
A scoring system built for one organ and one population
LI-RADS stands for Liver Imaging Reporting and Data System. It turns what a radiologist sees on a liver scan into a single category, from definitely benign to definitely cancer.
It is deliberately narrow. LI-RADS applies to adults with cirrhosis not caused by a vascular condition, to people with chronic hepatitis B with or without cirrhosis, and to people with current or prior hepatocellular carcinoma. RadiologyInfo adds liver transplant candidates. It is not used in people under 18, and not for lesions already proven benign by biopsy or removal.
The restriction is deliberate. The scoring only holds up when the underlying risk of liver cancer is already high. Applied to a healthy liver, the same imaging patterns would flag too many harmless spots.
NCI lists what puts a liver in that at-risk group: chronic hepatitis B or C, cirrhosis, heavy alcohol use, aflatoxin exposure, nonalcoholic steatohepatitis, tobacco use, and inherited conditions such as hemochromatosis and Wilson disease.
Why a scan can diagnose this cancer without a biopsy
Hepatocellular carcinoma, or HCC, has an unusual property. It behaves distinctively on contrast imaging, because it draws its blood supply from the hepatic artery while the surrounding liver is fed mostly by the portal vein.
So the tumor lights up early, then fades. NCI describes the standard test as a triple-phase, contrast-enhanced dynamic CT or MRI. For tumors 1 to 3 cm in a person at risk, a single study showing that pattern carries 95% to 100% specificity. That is high enough to diagnose without tissue.
A StatPearls chapter reports that LR-4 and LR-5 together reached 96.4% specificity and 65.4% sensitivity for HCC, including in lesions under 2 cm. High specificity, moderate sensitivity: the categories rarely mislabel a benign spot as cancer, but they do miss some cancers.
That same chapter notes that alpha-fetoprotein, a blood marker often drawn alongside, is optional in current AASLD practice guidance. Ultrasound remains the screening test of choice, though it is less sensitive for small lesions.
The features being graded
Radiologists score a short list of major features.
Non-rim arterial phase hyperenhancement. In the arterial phase, the observation is clearly brighter than the surrounding liver. The word non-rim matters. Brightness only around the edge points away from HCC.
Non-peripheral washout. From an earlier phase to a later one, the observation loses brightness relative to the liver around it. Again, not just at the edge.
Enhancing capsule. A smooth, uniform, sharply outlined ring of enhancement around the observation.
Threshold growth. The observation has grown by a defined amount over a defined interval compared with a prior scan. If your report cites threshold growth, ask for the prior measurement and the date it was taken.
Size. The largest diameter, which changes what the other features mean.
What the numbers mean
- LR-1: definitely benign.
- LR-2: probably benign.
- LR-3: intermediate probability of malignancy.
- LR-4: probably HCC.
- LR-5: definitely HCC. RadiologyInfo notes that biopsy is not needed to confirm this in most patients.
Ultrasound reports use a shorter scale, running from no evidence of cancer up to a lesion larger than 1 cm that needs contrast imaging next.
The letter categories
LR-M means probably or definitely malignant, but not specific for HCC. The pattern is different: rim enhancement in the arterial phase, peripheral washout, and enhancement that fills in centrally over time. Cholangiocarcinoma, a bile duct cancer, is a common cause. LR-M usually leads to biopsy, because the treatment path differs.
LR-TIV means tumor in vein. Definite enhancing tissue is seen inside a vein, which indicates vascular invasion.
LR-NC means not categorizable. The images were degraded or a required phase was missing. This is a technical result, not a reassuring one, and it usually means repeating the study.
The rule that surprises people
An observation under 10 mm cannot be called LR-5, no matter how classic it looks.
Small lesions are too easy to over-call. NCI describes the standard response for a lesion under 1 cm found during surveillance: close follow-up at 3-month intervals, using the same technique that found it.
So a small bright spot on your report is not a diagnosis being withheld. It is a spot that current imaging cannot resolve, being watched on a defined schedule.
What happens after each category
The category drives the next step rather than the treatment itself.
- LR-1 and LR-2: return to routine surveillance.
- LR-3: repeat or alternative imaging, often within a few months.
- LR-4: more imaging, a biopsy, or a multidisciplinary review.
- LR-5: treatment planning begins, usually without biopsy.
- LR-M: biopsy, because the cancer type must be established.
NCI notes that biopsy may be considered when two imaging tests fail to characterize a lesion larger than 1 cm in a high-risk patient.
Size and number then feed transplant decisions. NCI states the Milan criteria as a single HCC lesion smaller than 5 cm, or 2 to 3 lesions each smaller than 3 cm.
For staging, NCI describes the Barcelona Clinic Liver Cancer system as the most accepted. It combines tumor stage, liver function, physical status, and symptoms. The AJCC TNM system is less useful here, because it does not account for how well the liver is working.
Categories are not permanent
Ancillary features can nudge a category up or down. Published examples include restricted diffusion, moderate T2 brightness, fat inside the lesion, corona enhancement, and a mosaic internal pattern.
RadiologyInfo makes a related point: categories can change over time as liver disease progresses. An LR-3 today may be LR-3, LR-4, or LR-1 at the next scan.
Questions worth asking:
- Which major features were present, and which were absent?
- What was the size in millimeters, and what was it on the prior scan?
- Was the study technically adequate, or was any phase missing?
- Is the next step repeat imaging, biopsy, or treatment planning?
- Exactly when is the next scan due?
Sources
Words to know
Tap any term to see what it means.
Common questions
What does LI-RADS mean?
In general, LI-RADS is a system radiologists use to categorize liver findings, from probably benign to definitely hepatocellular carcinoma in the right setting.
Does it mean cancer?
The meaning depends heavily on liver disease history, imaging quality, and the exact LI-RADS category.
What should I ask next?
A practical next question is to ask which category was used, whether you are in a high-risk group, and whether follow-up imaging, biopsy, or liver specialist review is recommended.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Look up related pathology, imaging, biomarker, and treatment-response language.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Knowledge Check
0 of 3 answered
This self-assessment checks understanding of educational content only. It is not medical advice.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-07-20 what this meansLast updated: 2026-08-06Next planned review: 2027-07-20
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Editorial review complete. This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Editorial review complete — This page completed Cancer Explained's editorial checks (sources, safety, plain language, duplication). It has not been reviewed by a physician or other healthcare professional.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share